Key Decisions in HIV Care: Switching to Long-Acting ART - a podcast by Clinical Care Options

In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:

• ATLAS and FLAIR studies of long-acting injectable CAB + RPV
• ATLAS 2M dosing study
• FDA approval and DHHS statement on use of long-acting injectable ART
• Studies on whether an oral lead-in is needed

Presenter:

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Follow along with the slides at:
https://bit.ly/3hNfHII

See the entire program at:
https://bit.ly/2TXTYWx

 

Further episodes of CCO Infectious Disease Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options